Results 91 to 100 of about 4,697 (156)

Effect of Acalabrutinib in Combination with Bendamustine plus Rituximab on Survival Endpoints in Older Patients with Mantle Cell Lymphoma: Insights from the ECHO Trial

healthbook TIMES. Oncology Hematology
Mantle cell lymphoma (MCL) is a rare and often aggressive type of non-Hodgkin lymphoma that predominantly affects older adults and presents significant treatment challenges due to its clinical complexity and poor prognosis.
Adrian Schmidt
doaj   +1 more source

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

, 2020
Background: Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients ...
Wierda W. G., Egyed M., Woyach J. A., Ghia P., Sharman J. P., Jurczak W., Byrd J. C., Karlsson K., Walewska R., Coutre S., Fogliatto L. M., Izumi R., Patel P., Cymbalista F., Wang M. H., Janssens A., Corbett G., Munugalavadla V., Herishanu Y., Walker P., Follows G., Skarbnik A., Flinn I. W., Munir T., Wong S., Pagel J. M., Kamdar M., Salles G., Banerji V.   +28 more
core   +1 more source

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

, 2019
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation.
Pagel, John M, Patel, Priti, Woyach, Jennifer, Bibikova, Elena, Byrd, John C, Brown, Jennifer R, Wang, Min Hui, Frigault, Melanie M, Charuworn, Prista, Furman, Richard R, Awan, Farrukh T, Hillmen, Peter, Hamdy, Ahmed, Izumi, Raquel, Stephens, Deborah M, Linghu, Bolan, Schuh, Anna   +16 more
core   +1 more source

Abstracts of 14th International Symposium on Hodgkin Lymphoma

HemaSphere, Volume 10, Issue S2, October 2026.
wiley   +1 more source

Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization.

The efficacy and safety of acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, was evaluated in 2 phase 2 studies in hospitalized patients with coronavirus disease 2019 (COVID-19) who received acalabrutinib + best supportive care (BSC) versus BSC ...
Patel, Priti, Scheinberg, Phillip, Munugalavadla, Veerendra, Romero, José Omar Chacón, Sato, Victor A H, Robinson, Philip A, Fogliatto, Laura, Park, David J, Townsley, Danielle M, Guerreros, Alfredo, Meisenberg, Barry R, Prozesky, Hans W, Fonseca, Benedito A L, Gupta, Ashok, Zheng, Lianqing, Khoshnevis, Matt R   +15 more
core   +1 more source

Bruton’s tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice

Frontiers in Immunology
Sepsis is a systemic inflammatory response to a severe, life-threatening infection with organ dysfunction. Although there is no effective treatment for this fatal illness, a deeper understanding of the pathophysiological basis of sepsis and its ...
Kazuhiko Kawata, Shinya Hatano, Akemi Baba, Keisuke Imabayashi, Yoshihiro Baba   +4 more
doaj   +1 more source

Frontline Fixed-Duration Acalabrutinib Plus Venetoclax in Rapidly Progressive _IGHV_-Mutated CLL: A Case Report

healthbook TIMES. Oncology Hematology
# Introduction The phase III AMPLIFY trial established fixed-duration acalabrutinib plus venetoclax as an effective, all-oral, chemotherapy-free frontline therapy for chronic lymphocytic leukemia (CLL).
Young-Lan Song, Adrian Schmidt
doaj   +1 more source

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report

eJHaem
The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable.
Anna Nikkarinen, Ingrid Glimelius
doaj   +1 more source

The place of acalabrutinib-obinutuzumab combination in the first-line treatment of patients with chronic lymphocytic leukemia. [PDF]

Transl Cancer Res
Szymczyk A, Hus I.
europepmc   +1 more source

Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report. [PDF]

Am J Ophthalmol Case Rep
Shakarchi FF, Chacko JA, Chacko JG, Govindarajan R, Zent CS, Uwaydat SH.   +5 more
europepmc   +1 more source